FDA has approved vemurafenib (Zelboraf, Daiichi Sankyo and Genentech), the second melanoma drug this year to improve overall survival. Zelboraf is indicated for the treatment of patients with late-stage (metastatic) or unresectable melanoma, the most dangerous type of skin cancer.
The Institute for Safe Medication Practices is warning pharmacists, physicians, and nurses against misadministration of insulin through inappropriate dosing and treatment of hyperkalemia.
Systemic lupus erythematosus is a serious, potentially fatal autoimmune disease that affects between 300,000 to 1.5 million Americans of all races. Restless legs syndrome is a disruptive neurologic disorder that affects up to 10% of all Americans.
FDA has approved emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Complera, Gilead Sciences), a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.
FDA issued a warning last week that chronic high doses (400 mg/day to 800 mg/day) of fluconazole (Diflucan) during the first trimester of pregnancy may be associated with specific birth defects in infants. However, according to the Safety Alert released August 3, the risk does not appear to be associated with the single low dose of fluconazole (150 mg) that is used to treat vaginal yeast infection (candidiasis).
FDA has approved a subcutaneous (SC) formulation of abatacept (Orencia, Bristol-Myers Squibb) for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). It is the first biologic available in both SC and intravenous formulations for the treatment of RA.
FDA has issued a 90-day extension of the action date for Pfizer?s Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults 50 years of age and older.
The significant decrease in the death rate from the varicella virus, or chickenpox, can be attributed to the effectiveness of the chickenpox vaccine, according to a new study in a recent issue of Pediatrics.
FDA has received reports of serious central nervous system reactions when methylene blue is given to patients taking serotonergic psychiatric medications.
Improved glycemic control may help prevent heart failure, according to a study recently published in The Lancet.